HCG Kenya raises stake in AMIL to 50.10% via share acquisition
- HCG Kenya acquired 10 ordinary shares of AMIL from Meditec Systems Limited
- Stake in AMIL increased from 50% to 50.10% for consideration of KES 42,150
- AMIL reported FY26 turnover of ₹10.96 crore, up from nil in prior years
- Transaction completed on cash basis on October 5, 2026, without regulatory approvals
*this image is generated using AI for illustrative purposes only.
Healthcare Global Enterprises announced that its step-down subsidiary, Healthcare Global (Kenya) Private Limited (HCG Kenya), has increased its stake in Advanced Molecular Imaging Limited (AMIL) to 50.10%. The transaction was completed on October 5, 2026, converting AMIL from an associate into a subsidiary of HCG Kenya.
HCG Kenya entered into a Share Purchase Agreement with Meditec Systems Limited to acquire 10 ordinary shares of AMIL. The aggregate consideration for this acquisition was KES 42,150, which translates to approximately ₹31,288 as of the transaction date. The payment was made in cash on the same day the agreement was executed.
Transaction details
Prior to this acquisition, HCG Kenya held a 50% stake in AMIL. The purchase of the additional 10 shares increased its holding by approximately 0.10%, bringing the total shareholding to 50.10%. This change in ownership structure means AMIL is no longer classified as an associate but is now a step-down subsidiary of Healthcare Global Enterprises.
The filing confirmed that the transaction does not fall within the ambit of a related party transaction. No specific governmental or regulatory approvals were required for this acquisition.
About Advanced Molecular Imaging Limited
AMIL is incorporated under the laws of Kenya and operates in the healthcare sector, specifically in molecular and diagnostic imaging. The company was incorporated on October 7, 2016.
| Metric | Details |
|---|---|
| Target Company | Advanced Molecular Imaging Limited (AMIL) |
| Industry | Healthcare - Molecular Imaging / Diagnostic Imaging |
| Date of Incorporation | October 7, 2016 |
| Country of Presence | Kenya |
| Share Capital Structure | 10,000 Ordinary Shares of KES 100 each |
Financial performance of target
The disclosure provided turnover figures for AMIL for the last three fiscal years ending December 31. The company reported significant revenue generation in FY26 after recording nil turnover in the preceding two years.
| Fiscal Year Ending | Turnover (KES) | Turnover (INR) |
|---|---|---|
| December 31, 2025 | 156,281,949 | 109,563,210 |
| December 31, 2024 | Nil | Nil |
| December 31, 2023 | Nil | Nil |
What the numbers show
The acquisition cost of KES 42,150 for a 0.10% stake implies a valuation that contrasts sharply with AMIL's reported FY26 revenue of ₹10.96 crore. While the absolute monetary value of the transaction is minimal, the strategic shift from associate to subsidiary status consolidates control within the HCG group structure. The jump from nil revenue in FY24 and FY23 to over ₹10 crore in FY26 indicates recent operational commencement or significant business growth for the Kenyan entity.
Historical Stock Returns for Healthcare Global Enterprises
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -0.41% | -7.91% | -13.28% | +4.88% | -13.71% | 0.0% |
How will the consolidation of AMIL into HCG Kenya's financial statements impact Healthcare Global Enterprises' reported revenue and EBITDA margins in the upcoming quarters?
What specific operational drivers or new service lines enabled AMIL to generate ₹10.96 crore in turnover in FY26 after two years of nil revenue?
Does this acquisition signal a broader strategic expansion by Healthcare Global Enterprises into East African diagnostic imaging markets beyond its current footprint?
16
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
